Key updates to the treatment of drug-resistant tuberculosis: rapid communication, June 2024

A rapid communication released by the World Health Organization (WHO) Global Tuberculosis Programme has announced upcoming updates to the guidance on the treatment of drug-resistant tuberculosis (DR-TB). These updates include a new 6-month regimen based on bedaquiline (B), delamanid (D), and linezolid (L) in combination with either levofloxacin (Lfx) or clofazimine (C) or both and a group of 9-month regimens for the treatment of patients with MDR/RR-TB without fluoroquinolone resistance. This Rapid Communication is released in advance of updated WHO consolidated guidelines expected in early 2025, to inform national TB programmes and other stakeholders of key changes in the treatment of DR-TB and to allow for rapid transition and planning at the country level.